Modified—modified radical mastoidectomy

Dosemane, Deviprasad; Khadilkar, Meera Niranjan; Parvathareddy, Navya

doi:10.1007/s00405-023-08021-w

Cited by 2 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Modified radical mastoidectomy is the primary treatment method for suppurative otitis media. 1 2 The main objective is to remove the lesion, achieve a dry ear and preserve or reconstruct hearing. 3 This surgical procedure involves limited operating space and numerous important anatomical structures, 4 which is typically conducted under a microscope, maintaining a clear surgical field of view is crucial, as a blurred field may lead to several issues, including difficulty in identifying anatomical landmarks, longer operative time and increased risk of surgical complications.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of intravenous tranexamic acid in microscopic modified radical mastoidectomy: a study protocol for a prospective, randomised, double-blind controlled trial

Zhang,

Ding,

Feng

et al. 2024

BMJ Open

View full text Add to dashboard Cite

IntroductionRadical mastoidectomy is a common procedure for chronic suppurative otitis media, typically performed under a microscope. The smooth operation is closely related to the clarity of the operative field. Our trial is designed to investigate whether the intravenous administration of tranexamic acid (TXA) can improve the clarity of the operative field, reduce the operative time, and increase surgeon satisfaction.Methods and analysisThis study is a prospective, randomised, double-blinded, controlled trial that aims to investigate the effects of TXA on patients with otitis media. The trial will include patients between the ages of 18 and 65 who will be randomly assigned to either the TXA group or the control group. In the TXA group, patients will receive 1 g of TXA diluted to 20 mL of normal saline before anaesthesia induction while the control group will receive 20 mL of normal saline. The primary outcome measure will be the Modena Bleeding Score, which will assess the clarity of the surgical field. Secondary outcomes will include the surgeon’s satisfaction with surgical conditions, operation time, laboratory measurements (prothrombin time, activated partial thromboplastin time, fibrin degradation products, D-dimer) and levels of inflammatory factors (such as IL-6) at 24 hours postoperatively. In addition, the incidence of general adverse reactions such as postoperative nausea, vomiting and dizziness; serious adverse events such as arterial and venous thromboembolism, myocardial infarction and epilepsy within 90 days will be compared between the two groups.Ethics and disseminationThe protocol was approved by the Ethics Committee of Peking University People’s Hospital (2021PHB173-001), on 19 July 2021. The trial results will be submitted for publication in a peer-reviewed journal.Trial registration numberChiCTR2100049183.

show abstract

Section: Introductionmentioning

confidence: 99%